New lens option may reduce need for glasses after cataract surgery in glaucoma patients

NCT ID NCT07436871

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test whether a special type of lens implant (extended depth-of-focus, or EDOF) can give better vision and more satisfaction than standard monofocal lenses for people with both glaucoma and cataracts. About 74 adults with early-to-moderate open-angle glaucoma will receive the same type of lens in both eyes during cataract surgery. The main goal is to see if the EDOF lens improves intermediate vision (like computer distance) without causing more visual disturbances.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Extended depth-of-focus (EDOF) intraocular lens

What this could lead to

If successful, this could show that EDOF lenses are a safe option for glaucoma patients, offering better intermediate vision and less need for glasses after cataract surgery.

What could go wrong

This is a small, early-stage trial (74 people) that hasn't started yet. Results may not apply to all glaucoma patients, and EDOF lenses might cause more glare or halos than monofocal lenses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract glaucoma 1, open angle, l open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.